Literature DB >> 22120039

Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer.

R M Rodriguez1, C Huidobro, R G Urdinguio, C Mangas, B Soldevilla, G Domínguez, F Bonilla, A F Fernandez, M F Fraga.   

Abstract

The bromodomain protein BRD4 is involved in cell proliferation and cell cycle progression, primarily through its role in acetylated chromatin-dependent regulation of transcription at targeted loci. Here, we show that BRD4 is frequently downregulated by aberrant promoter hypermethylation in human colon cancer cell lines and primary tumors. Ectopic re-expression of BRD4 in these colon cancer cell lines markedly reduced in vivo tumor growth, suggesting a role of BRD4 in human colon cancer.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22120039     DOI： 10.1007/s00109-011-0837-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


  15 in total

1.  A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.

Authors:  A Dey; J Ellenberg; A Farina; A E Coleman; T Maruyama; S Sciortino; J Lippincott-Schwartz; K Ozato
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription.

Authors:  Anup Dey; Akira Nishiyama; Tatiana Karpova; James McNally; Keiko Ozato
Journal:  Mol Biol Cell       Date:  2009-10-07       Impact factor: 4.138

3.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Authors:  Mario F Fraga; Esteban Ballestar; Ana Villar-Garea; Manuel Boix-Chornet; Jesus Espada; Gunnar Schotta; Tiziana Bonaldi; Claire Haydon; Santiago Ropero; Kevin Petrie; N Gopalakrishna Iyer; Alberto Pérez-Rosado; Enrique Calvo; Juan A Lopez; Amparo Cano; Maria J Calasanz; Dolors Colomer; Miguel Angel Piris; Natalie Ahn; Axel Imhof; Carlos Caldas; Thomas Jenuwein; Manel Esteller
Journal:  Nat Genet       Date:  2005-03-13       Impact factor: 38.330

4.  Regulation of aurora B expression by the bromodomain protein Brd4.

Authors:  Jianxin You; Qing Li; Chong Wu; Jina Kim; Matthias Ottinger; Peter M Howley
Journal:  Mol Cell Biol       Date:  2009-07-13       Impact factor: 4.272

5.  Control of inducible gene expression by signal-dependent transcriptional elongation.

Authors:  Diana C Hargreaves; Tiffany Horng; Ruslan Medzhitov
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

6.  Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4.

Authors:  Cheng-Ming Chiang
Journal:  F1000 Biol Rep       Date:  2009-12-15

7.  Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.

Authors:  Santiago Ropero; Javier Abel Menéndez; Alejandro Vázquez-Martín; Sagrario Montero; Hernán Cortés-Funes; Ramon Colomer
Journal:  Breast Cancer Res Treat       Date:  2004-07       Impact factor: 4.872

8.  Bromodomain 4 activation predicts breast cancer survival.

Authors:  Nigel P S Crawford; Jude Alsarraj; Luanne Lukes; Renard C Walker; Jennifer S Officewala; Howard H Yang; Maxwell P Lee; Keiko Ozato; Kent W Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-21       Impact factor: 11.205

9.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

Authors:  Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

10.  A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase.

Authors:  Tetsuo Maruyama; Andrea Farina; Anup Dey; JaeHun Cheong; Vladimir P Bermudez; Tomohiko Tamura; Selvaggia Sciortino; Jon Shuman; Jerard Hurwitz; Keiko Ozato
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272
View more
  29 in total

1.  CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

Authors:  Mark L McCleland; Kathryn Mesh; Edward Lorenzana; Vivek S Chopra; Ehud Segal; Colin Watanabe; Benjamin Haley; Oleg Mayba; Murat Yaylaoglu; Florian Gnad; Ron Firestein
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

2.  Role of BRD4 in hematopoietic differentiation of embryonic stem cells.

Authors:  Ramon M Rodriguez; Beatriz Suarez-Alvarez; Ruben Salvanés; Covadonga Huidobro; Estela G Toraño; Jose L Garcia-Perez; Carlos Lopez-Larrea; Agustin F Fernandez; Clara Bueno; Pablo Menendez; Mario F Fraga
Journal:  Epigenetics       Date:  2014-01-20       Impact factor: 4.528

Review 3.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

4.  BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos.

Authors:  W Liu; P Stein; X Cheng; W Yang; N-Y Shao; E E Morrisey; R M Schultz; J You
Journal:  Cell Death Differ       Date:  2014-08-22       Impact factor: 15.828

5.  DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase.

Authors:  Teresa Morales-Ruiz; María Victoria García-Ortiz; Iván Devesa-Guerra; Laura Raya-Ruiz; Juan R Tejedor; Gustavo F Bayón; Marta I Sierra; Mario F Fraga; Rafael R Ariza; Teresa Roldán-Arjona
Journal:  Epigenetics       Date:  2018-02-07       Impact factor: 4.528

6.  BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.

Authors:  Ballachanda N Devaiah; Brian A Lewis; Natasha Cherman; Michael C Hewitt; Brian K Albrecht; Pamela G Robey; Keiko Ozato; Robert J Sims; Dinah S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

7.  Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma.

Authors:  Apostolos Zaravinos; Peggy Kanellou; George I Lambrou; Demetrios A Spandidos
Journal:  Tumour Biol       Date:  2014-01-31

8.  The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Authors:  A Esteve-Arenys; J G Valero; A Chamorro-Jorganes; D Gonzalez; V Rodriguez; I Dlouhy; I Salaverria; E Campo; D Colomer; A Martinez; G Rymkiewicz; P Pérez-Galán; A Lopez-Guillermo; G Roué
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

9.  Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression.

Authors:  Xiangming Hu; Xiaodong Lu; Runzhong Liu; Nanping Ai; Zhenhua Cao; Yannan Li; Jiangfang Liu; Bin Yu; Kai Liu; Huiping Wang; Chao Zhou; Yu Wang; Aidong Han; Feng Ding; Ruichuan Chen
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

10.  Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.

Authors:  Ranran Wang; Wei Liu; Christine M Helfer; James E Bradner; Jason L Hornick; Susan M Janicki; Christopher A French; Jianxin You
Journal:  Cancer Res       Date:  2014-04-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.